Hormonal
In overweight or obese adults, tirzepatide produces significantly greater weight loss than semaglutide over a 6-month period, particularly in patients without diabetes.
If you are overweight or obese and considering medication, tirzepatide appears to offer greater weight loss benefits than semaglutide over a 6-month period, especially if you do not have diabetes. However, real-world effectiveness can vary based on adherence and cost, so discuss these factors with your provider.
In this study of patients who were overweight or obese, tirzepatide was associated with greater weight loss over 6 months of follow-up than semaglutide overall and in patients without diabetes.
Why this rating
Real-world retrospective cohort study; lower than RCTs due to potential unmeasured confounding and lack of dose/titration data.
Source
Real‐world effectiveness of tirzepatide versus semaglutide for weight loss in overweight or obese patients in an ambulatory care setting
Huong Trinh et al. · Diabetes Obesity and Metabolism · 2025
DOI 10.1111/dom.16343
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →